Targeting CD22 in B-cell Malignancies: Current Status and Clinical Outlook

CD22 Antigen Is Broadly Expressed on Lung Cancer Cells and Is a Target for Antibody-Based Therapy

(2012) J. M. Tuscano et al.   CANCER RESEARCH

Antibody–drug conjugates – a perfect synergy

(2012) John R Adair et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Differences in drug approval processes of 3 regulatory agencies: a case study of gemtuzumab ozogamicin

(2012) Tetsuya Tanimoto et al.   INVESTIGATIONAL NEW DRUGS

Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia

(2012) Robert J. Kreitman et al.   JOURNAL OF CLINICAL ONCOLOGY

Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study

(2012) Hagop Kantarjian et al.   LANCET ONCOLOGY

Efficacy of a CD22-targeted antibody-saporin conjugate in a xenograft model of precursor-B cell acute lymphoblastic leukemia

(2012) Jason Kato et al.   LEUKEMIA RESEARCH

Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy

(2012) H. Wei et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Efficacy and toxicity of a CD22-targeted antibody-saporin conjugate in a xenograft model of non-Hodgkin’s lymphoma

(2012) Jason Kato et al.   OncoImmunology

Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma

(2011) I. N. M. Micallef et al.   BLOOD

Treatment of Hematologic Malignancies with Immunotoxins and Antibody-Drug Conjugates

(2011) D. J. FitzGerald et al.   CANCER RESEARCH

Antibody-Drug Conjugates of Calicheamicin Derivative: Gemtuzumab Ozogamicin and Inotuzumab Ozogamicin

(2011) A. D. Ricart   CLINICAL CANCER RESEARCH

Immunotoxins with decreased immunogenicity and improved activity

(2011) Ira Pastan et al.   LEUKEMIA & LYMPHOMA

Targeting B lymphoma with nanoparticles bearing glycan ligands of CD22

(2011) Weihsu C. Chen et al.   LEUKEMIA & LYMPHOMA

Epratuzumab-SN-38: A New Antibody-Drug Conjugate for the Therapy of Hematologic Malignancies

(2011) R. M. Sharkey et al.   MOLECULAR CANCER THERAPEUTICS

In vivo targeting of B-cell lymphoma with glycan ligands of CD22

(2010) W. C. Chen et al.   BLOOD

Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP

(2010) John F. DiJoseph et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Anti-CD22 Immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-Positive Hematologic Malignancies of Childhood: Preclinical Studies and Phase I Clinical Trial

(2010) A. S. Wayne et al.   CLINICAL CANCER RESEARCH

Efficacy, Biodistribution, and Pharmacokinetics of CD22-Targeted Pegylated Liposomal Doxorubicin in a B-cell Non-Hodgkin's Lymphoma Xenograft Mouse Model

(2010) J. M. Tuscano et al.   CLINICAL CANCER RESEARCH

Investigational antibody-drug conjugates for hematological malignancies

(2010) Andrew G Polson et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Oversight of Fast-Track Drug Approval by FDA Stuck in Low Gear, Critics Say

(2010) Mike Mitka   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

High Rates of Durable Responses With Anti-CD22 Fractionated Radioimmunotherapy: Results of a Multicenter, Phase I/II Study in Non-Hodgkin's Lymphoma

(2010) Franck Morschhauser et al.   JOURNAL OF CLINICAL ONCOLOGY

Vitamin D Insufficiency and Prognosis in Non-Hodgkin's Lymphoma

(2010) Matthew T. Drake et al.   JOURNAL OF CLINICAL ONCOLOGY

CD22 Is a Recycling Receptor That Can Shuttle Cargo between the Cell Surface and Endosomal Compartments of B Cells

(2010) M. K. O'Reilly et al.   JOURNAL OF IMMUNOLOGY

FDA Increases Focus on Postmarketing Studies

(2010) M. Goozner   JNCI-Journal of the National Cancer Institute

Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma

(2010) A G Polson et al.   LEUKEMIA

Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma

(2009) Vincent Ribrag et al.   CANCER

Dose, timing, schedule, and the choice of targeted epitope alter the efficacy of anti-CD22 immunotherapy in mice bearing human lymphoma xenografts

(2009) Robert T. O’Donnell et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD)

(2009) Robert T. O’Donnell et al.   INVESTIGATIONAL NEW DRUGS

Statin Use and Prognosis in Patients With Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in the Rituximab Era

(2009) Grzegorz S. Nowakowski et al.   JOURNAL OF CLINICAL ONCOLOGY

Developmental Acquisition of the Lyn-CD22-SHP-1 Inhibitory Pathway Promotes B Cell Tolerance

(2009) A. J. Gross et al.   JOURNAL OF IMMUNOLOGY

Durable complete responses from therapy with combined epratuzumab and rituximab

(2008) John P. Leonard et al.   CANCER

Therapy of Advanced B-Lymphoma Xenografts with a Combination of 90Y-anti-CD22 IgG (Epratuzumab) and Unlabeled Anti-CD20 IgG (Veltuzumab)

(2008) M. J. Mattes et al.   CLINICAL CANCER RESEARCH

CD22: an inhibitory enigma

(2008) Jennifer A. Walker et al.   IMMUNOLOGY

Chemoimmunotherapy Reinduction With Epratuzumab in Children With Acute Lymphoblastic Leukemia in Marrow Relapse: A Children's Oncology Group Pilot Study

(2008) Elizabeth A. Raetz et al.   JOURNAL OF CLINICAL ONCOLOGY

Reinduction Platform for Children With First Marrow Relapse of Acute Lymphoblastic Leukemia: A Children's Oncology Group Study

(2008) Elizabeth A. Raetz et al.   JOURNAL OF CLINICAL ONCOLOGY